GlassScriptPhysician profile
Eric Daniel Sensenbrenner
NPI 1083174148
$5,029.93
in general payments reported to CMS, 2019-2025
39 companies · $49.94 in 2025
The $49.94 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $877 · 2023: $2,963 · 2024: $1,140 · 2025: $49.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,152.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $691.79 | 2022-2024 | |
| Abbvie INC. | $674.93 | 2022-2024 | Ubrelvy, Linzess, Vraylar |
| Novo Nordisk INC | $494.62 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $387.27 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.87 | 2022-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $319.64 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $255.94 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $222.55 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $154.54 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $145.91 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $120.06 | 2022-2023 | Shingrix, Arexvy |
| Heartflow, INC. | $92.20 | 2023 | Ffrct |
| Xeris Pharmaceuticals, INC. | $92.12 | 2022-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $89.29 | 2022-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.93 | 2022-2023 | Xifaxan, Trulance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $79.93 | 2022-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $77.86 | 2022 | |
| Insightec,INC | $63.45 | 2023 | Exablate |
| Azurity Pharmaceuticals, INC. | $59.76 | 2023 | Edarbi, Horizant |
| Idorsia Pharmaceuticals US INC | $52.84 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $44.69 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $43.80 | 2023 | Injectafer |
| Neos Therapeutics, LP | $39.79 | 2022-2023 | Adzenys Xr-Odt |
| Paratek Pharmaceuticals, INC. | $38.84 | 2022 | |
| Sumitomo Pharma America, INC. | $35.87 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $35.41 | 2022-2023 | Belsomra |
| Inspire Medical Systems, INC. | $34.77 | 2023-2024 | Inspire |
| Bausch Health US, LLC | $30.69 | 2023 | Wellbutrin, Aplenzin |
| Boston Scientific Corporation | $27.75 | 2025 | Wavewriter Alpha Prime 16 |
| Ibsa Pharma INC. | $27.27 | 2022-2023 | Tirosint, Licart |
| Axsome Therapeutics, INC. | $24.48 | 2024 | Auvelity |
| Corcept Therapeutics | $23.37 | 2023 | Korlym |
| Teva Pharmaceuticals USA, INC. | $19.87 | 2022 | |
| Renalytix Ai, INC. | $19.35 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Tolmar, INC. | $18.22 | 2023 | |
| Supernus Pharmaceuticals, INC. | $17.55 | 2022 | |
| Eisai INC. | $17.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.91 | 2023 | Seglentis, Livalo |
| Shield Therapeutics INC | $14.61 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sensenbrenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.